Study of Colon GVAX and Cyclophosphamide in Patients With Metastatic Colorectal Cancer

Phase 1 Completed 9 enrolled Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate the safety and feasibility of vaccination with two irradiated allogeneic colorectal carcinoma cells administered with a GM-CSF producing bystander cell line in sequence with an immunomodulatory dose of Cyclophosphamide

Timeline

Start: 2008-03
Primary completion: 2011-08
Completion: 2013-01

Publications

Results Zheng L, Edil BH, Soares KC, El-Shami K, Uram JN, Judkins C, Zhang Z, Onners B, Laheru D, Pardoll D, Jaffee EM, Schulick RD. A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer. Ann Surg Oncol. 2014 Nov;21(12):3931-7. doi: 10.1245/s10434-014-3844-x. Epub 2014 Jun 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Colon GVAX	Vaccine	1.4e+08 cells	Other
Subject	Colon GVAX	Vaccine	7e+08 cells	Other
Subject	Cyclophosphamide	Other / unclassified	200 mg/m2	Intravenous

Study of Colon GVAX and Cyclophosphamide in Patients With Metastatic Colorectal Cancer

Summary

Timeline

Publications

Drugs

Indications